A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 5, 2003, Pages 433-438

  Hong, Ruey Long ^a   Tseng, Yun Long ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Doxorubicin; Inoperable hepatocellular carcinoma; Liposome; Liver function

Indexed keywords

DOXORUBICIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUOROMETRY; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TOXICITY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

EID: 0037680639     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0583-2     Document Type: Article

References (29)

1. Albalak A, Zeidel ML, Zucker SD, Jackson AA, Donovan JM (1996) Effects of submicellar bile salt concentrations on biological membrane permeability to low molecular weight non-ionic solutes. Biochemistry 35:7936-7945
2. Alberts DS, Garcia DJ (1997) Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54 [Suppl 4]:30-35
3. Bolognesi M, Merkel C, Bianco S, Angeli P, Sacerdoti D, Amodio P, Gatta A (1994) Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology 19:628-634
4. Bukowski RM, Legha S, Saiki J, Eyre HJ, O'Bryan R (1982) Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study. Cancer Treat Rep 66:1651-1652
5. Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY, Lee SD (1998) Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78:34-39
6. Cheirsilpa A, Leelasethakul S, Auethaveekiat V, Maoleekulpriroj S, Kangsumrit N, Thanakaravit P, Phanthumjida P (1989) High-dose mitomycin C: activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 24:50-53
7. 2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 68:487-491
8. Daniele B, De Vivo R, Perrone F, Lastoria S, Tambaro R, Izzo F, Fiore F, Vallone P, Pignata S (2000) Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis. Anticancer Res 20:1249-1251
9. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743
10. Falkson G, Burger W (1995) A phase II trial of vindesine in hepatocellular cancer. Oncology 52:86-87
11. Falkson G, Cnaan A, Simson IW, Dayal Y, Falkson H, Smith TJ, Haller DG (1990) A randomized phase II study of acivicin and 4′-deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study. Am J Clin Oncol 13:510-515
12. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 [Suppl 4]:15-21
13. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992
14. Gebbia V, Maiello E, Serravezza G, Giotta F, Testa A, Borsellino N, Pezzella G, Colucci G (1999) 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Anticancer Res 19:1407-1410
15. Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mossner J, Berr F (2000) A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 11:113-114
16. Hong RL, Tseng YL (2001) Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 91:1826-1833
17. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH (1999) Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 5:3645-3652
18. Hong RL, Tseng YL, Chang FH (2000) Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study. Ann Oncol 11:349-353
19. Lin J, Shiu W, Leung WT, Tao M, Leung N, Lau WY, Li AK (1993) Phase II study of high-dose ifosfamide in hepatocellular carcinoma. Cancer Chemother Pharmacol 31:338-339
20. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T (1998) Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 12:111-126
21. Rutgers HC, Stradley RP, Johnson SE (1988) Serum bile acid analysis in dogs with experimentally induced cholestatic jaundice. Am J Vet Res 49:317-320
22. Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC (2001) Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85:1850-1852
23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
24. Storm G, ten Kate MT, Working PK, Bakker-Woudenberg IA (1998) Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin Cancer Res 4:111-115
25. Tetef M, Doroshow J, Akman S, Coluzzi P, Leong L, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G (1995) 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13:460-463
26. Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald. JS (1997) Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs 15:257-260
27. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH (2000) Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89:750-756
28. Yeo W, Chan KK, Mukwaya G, Ross M, Leung WT, Ho S, Chan AT, Johnson PJ (1999) Phase II studies with DaunoX-ome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. Cancer Chemother Pharmacol 44:124-130
29. Yoshino M, Okazaki N, Yoshida T, Kanda Y, Miki M, Oda H, Sasagawa Y, Hayashi S, Hashimoto N (1989) A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn J Clin Oncol 19:120-122